Format

Send to

Choose Destination
Arterioscler Thromb Vasc Biol. 2019 Feb 14:ATVBAHA118312037. doi: 10.1161/ATVBAHA.118.312037. [Epub ahead of print]

Chemokines as Therapeutic Targets in Cardiovascular Disease.

Author information

1
From the Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University, Germany (H.N.).
2
Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (C.W., R.R.K.).
3
Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, the Netherlands (C.W., R.R.K).
4
DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Germany (C.W.).

Abstract

With the incidence and impact of atherosclerotic cardiovascular disease and its clinical manifestations still rising, therapeutic options that target the causal mechanisms of this disorder are highly desired. Since the CANTOS trial has demonstrated that lowering inflammation can be beneficial, focusing on mechanisms underlying inflammation, for example, leukocyte recruitment, is feasible. Being key orchestrators of leukocyte trafficking, chemokines have not lost their attractiveness as therapeutic targets, despite the difficult road to drug approval thus far. Still, innovative therapeutic approaches are being developed, paving the road towards the first chemokine-based therapeutic against inflammation. In this overview, recent developments for chemokines and for the chemokine-like factor macrophage MIF (migration inhibitory factor) will be discussed.

KEYWORDS:

atherosclerosis; bone marrow; cardiovascular disease; chemokines; myocardial infarction

PMID:
30760014
DOI:
10.1161/ATVBAHA.118.312037

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center